News | Breast Imaging | December 21, 2020

Global Breast Imaging Technologies Market Opportunity Analysis and Industry Forecast 2020-2030

The global breast imaging technologies market was valued at USD 3.54 billion in 2019 and is projected to surpass USD 7.43 billion by 2030, expanding at a CAGR of 6.90% during the forecast period from 2020 to 2030.

Getty Images

December 21, 2020 — The "Breast Imaging Technologies Market by Technology - Global Opportunity Analysis and Industry Forecast, 2020-2030" report is now available from ResearchAndMarkets.com.

The global breast imaging technologies market was valued at USD 3.54 billion in 2019 and is projected to surpass USD 7.43 billion by 2030, expanding at a CAGR of 6.90% during the forecast period from 2020 to 2030.

Increasing incidences of breast diseases in women, especially breast cancer is fuelling the demand for breast imaging technologies. Also, the growth of the global breast imaging technologies market can be attributed to the increasing initiatives by government and non-government organizations to raise awareness regarding the advantages of early cancer detection. Moreover, technological advancements in breast imaging modalities and development of the advanced healthcare infrastructures are contributing to the market growth.

However, high cost of imaging technologies, errors associated with screening process, stringent regulations, and lengthy approval processes are anticipated to hamper the breast imaging technologies market during the forecast period. On the other hand, increasing investments in healthcare sector, campaigns to reduce incidences of breast cancer, and growing R&D in the medical sector are creating opportunities for the breast imaging technology providers.

The breast imaging technologies market has been segmented based on product type and geography. In terms of product type, the breast imaging technologies market is bifurcated into ionizing breast imaging technologies and non-ionizing breast imaging technologies. The ionizing segment is further divided into analog mammograph, full-field digital mammography (FFDM), 3D breast tomosynthesis, positron emission tomography/computed tomography (PET/CT), molecular breast imaging/breast-specific gamma imaging (MBI/BSGI), cone beam computed tomography (CBCT), and positron emission mammography (PEM). The non-ionizing segment is sub-segmented into breast MRI, breast ultrasound, optical imaging, automated whole breast ultrasound (AWBU), and breast thermography. On the basis of geography, the market is split into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

North America is expected to dominate the global breast imaging market, accounting for a significant market share due to factors such as well-established healthcare infrastructures, better reimbursement facility, high adoption of advanced medical technologies, high R&D investment, and presence of key players.

The market in Asia-Pacific is estimated to grow at a substantial CAGR during the forecast period, owing to increasing government & non-government initiatives to prevent breast cancer, and constant development in the healthcare infrastructures.

For more information: https://www.researchandmarkets.com/r/rm07ji

Related Content

This is an example of 3-D ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

This is an example of TriVu ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

Feature | Breast Imaging | September 15, 2021 | By Jennifer Meade
The...
While the Mammography Quality Standards Act (MQSA) and the introduction of EQUIP (Enhancing Quality Using the Inspection Program) have been successful in standardizing and enhancing mammographic imaging quality, inadequate breast positioning can dramatically impact the ability of radiologists and technicians to quickly and accurately detect breast cancer and potentially malignant lesions in their patients

Getty Images

Feature | Mammography | September 15, 2021 | By Christopher Austin, M.D. and Randy D. Hicks, M.D., MBA
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
According to ARRS’ American Journal of Roentgenology (AJR), immediately reading screening mammograms during the coronavirus disease (COVID-19) pandemic promises a new and improved paradigm—reducing care disparities, while increasing the speed of diagnostic workup.

Flow Chart of Patient Selection

News | Breast Imaging | September 09, 2021
September 9, 202
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...
The researchers say there is currently a lack of good quality evidence to support a policy of replacing human radiologists with artificial intelligence (AI) technology when screening for breast cancer.

Getty Images

News | Artificial Intelligence | September 02, 2021
September 2, 2021 — Humans still seem to be better than technology when it comes to the accuracy of spotting possible
Building on prior success combining Cyclin-Dependent Kinase (CDK) inhibitors with hormone therapy to treat breast cancer, researchers are now exploring the potential integration of CDK inhibitors with radiotherapy

Schematic overview of cell cycle regulation, with an emphasis on radiotherapy-induced pathways and CDK/cyclin regulation. In M phase and in G2 resting phase, cancer cells are respectively very sensitive and moderately sensitive to radiation injury, whereas in G1 phase and in S phase, cancer cells are moderately resistant to radiation injury. Irradiation induces G1 and G2 cell cycle checkpoint activation and DNA repair. Most cancer cells are defective in G1 checkpoint, commonly due to the mutations/alterations of the key regulators of the G1 checkpoint, but contain a functional G2 checkpoint. Figure courtesy of The International Journal of Molecular Sciences

News | Radiation Therapy | August 18, 2021
August 18, 2021 — Building on prior success combining Cyclin-Dependent Kinase (CDK) inhibitors with hormone therapy t
DenseBreast-info.org (DB-I) announced that the European Society of Radiology (ESR) now links to DB-I website and educational materials as a resource for members about the screening and risk implications of dense breast tissue.
News | Breast Density | August 13, 2021
August 13, 2021 —